# Xiuning Le

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6488852/publications.pdf

Version: 2024-02-01

| 53 | 3,019 | 257450 24 | 189892 50 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 55 | 55 | 55 | 3282 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Poziotinib for Patients With HER2 Exon 20 Mutant Nonâ€“Small-Cell Lung Cancer: Results From a Phase II Trial. Journal of Clinical Oncology, 2022, 40, 702-709. | 1.6 | 53 |
| 2 | Poziotinib in Nonâ€“Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial. Journal of Clinical Oncology, 2022, 40, 710-718. | 1.6 | 72 |
| 3 | Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice. Clinical Cancer Research, 2022, 28, 1117-1126. | 7.0 | 52 |
| 4 | Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review. Clinical Lung Cancer, 2022, 23, 195-207. | 2.6 | 22 |
| 5 | INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance. Future Oncology, 2022, 18, 1039-1054. | 2.4 | 30 |
| 6 | Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management. Clinical Lung Cancer, 2022, 23, 320-332. | 2.6 | 5 |
| 7 | In Response. Journal of Thoracic Oncology, 2022, 17, e39. | 1.1 | 0 |
| 8 | Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma. Journal of Thoracic Oncology, 2022, 17, 779-792. | 1.1 | 50 |
| 9 | Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection. Clinical Cancer Research, 2022, , . | 7.0 | 3 |
| 10 | Clinical response to tepotinib according to circulating tumor (ct) DNA biomarkers in patients with advanced NSCLC with high-level MET amplification (METamp) detected by liquid biopsy (LBx).. Journal of Clinical Oncology, 2022, 40, 9121-9121. | 1.6 | 8 |
| 11 | Real-world effectiveness of immune checkpoint inhibitors alone or in combination with chemotherapy in metastatic nonâ€“small cell lung cancer.. Journal of Clinical Oncology, 2022, 40, 9055-9055. | 1.6 | 0 |
| 12 | Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Nonâ€“Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab. JAMA Network Open, 2022, 5, e2215589. | 5.9 | 15 |
| 13 | Abstract CT536: Tepotinib efficacy and safety in patients with MET exon 14 (METex14) skipping NSCLC. Cancer Research, 2022, 82, CT536-CT536. | 0.9 | 1 |
| 14 | Limited benefit from the addition of immunotherapy to chemotherapy in TKI-refractory EGFR-mutant lung adenocarcinoma.. Journal of Clinical Oncology, 2022, 40, e21169-e21169. | 1.6 | 0 |
| 15 | Abstract LB078: Tumor genomics in patients (pts) with advanced epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib therapy in the Phase II ORCHARD study. Cancer Research, 2022, 82, LB078-LB078. | 0.9 | 4 |
| 16 | Tepotinib in Asian patients with advanced NSCLC with MET exon 14 (METex14) skipping.. Journal of Clinical Oncology, 2022, 40, 9120-9120. | 1.6 | 1 |
| 17 | innovaTV 207: New combination dosing cohorts in the open label phase 2 study of tisotumab vedotin in solid tumors.. Journal of Clinical Oncology, 2022, 40, TPS6100-TPS6100. | 1.6 | 2 |
| 18 | Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC. Journal of Thoracic Oncology, 2021, 16, 205-215. | 1.1 | 149 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Altered Regulation of HIF-1Î± in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype. Journal of Thoracic Oncology, 2021, 16, 439-451. | 1.1 | 34 |
| 20 | Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592199297. | 3.2 | 40 |
| 21 | Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nature Medicine, 2021, 27, 504-514. | 30.7 | 357 |
| 22 | Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck. Head and Neck, 2021, 43, 1592-1603. | 2.0 | 2 |
| 23 | Heterogeneity in MET-Aberrant NSCLC. Journal of Thoracic Oncology, 2021, 16, 504-506. | 1.1 | 9 |
| 24 | Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. Journal of Thoracic Oncology, 2021, 16, 583-600. | 1.1 | 62 |
| 25 | Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD). Clinical Lung Cancer, 2021, 22, 601-606. | 2.6 | 31 |
| 26 | Estrogen Promotes Resistance to Bevacizumab in Murine Models of NSCLC. Journal of Thoracic Oncology, 2021, 16, 2051-2064. | 1.1 | 6 |
| 27 | Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. , 2021, 9, e002891. | | 107 |
| 28 | ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC. Cancer Cell, 2021, 39, 1178-1180. | 16.8 | 6 |
| 29 | Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature, 2021, 597, 732-737. | 27.8 | 185 |
| 30 | CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunology, Immunotherapy, 2021, 70, 1965-1976. | 4.2 | 14 |
| 31 | Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations. JTO Clinical and Research Reports, 2021, 2, 100237. | 1.1 | 8 |
| 32 | Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. Nature Communications, 2021, 12, 6655. | 12.8 | 24 |
| 33 | Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Nonâ€“Small-Cell Lung Cancer Harboring MET Exon 14 Skipping. JCO Precision Oncology, 2021, 5, 1802-1812. | 3.0 | 9 |
| 34 | Î²-Adrenergic Signaling in Lung Cancer: A Potential Role for Beta-Blockers. Journal of NeuroImmune Pharmacology, 2020, 15, 27-36. | 4.1 | 35 |
| 35 | Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation. Oncogene, 2020, 39, 1846-1859. | 5.9 | 29 |
| 36 | Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. Lung Cancer, 2020, 149, 33-40. | 2.0 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Emerging Therapies in Thoracic Malignanciesâ€"Immunotherapy, Targeted Therapy, and T-Cell Therapy in Nonâ€"Small Cell Lung Cancer. Surgical Oncology Clinics of North America, 2020, 29, 555-569. | 1.5 | 6 |
| 38 | New Verse for a Familiar Song: Small Molecule Inhibitors for MET exon 14 Skipping Non-Small Cell Lung Cancer. Oncologist, 2020, 25, 822-825. | 3.7 | 9 |
| 39 | A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. Science Translational Medicine, 2020, 12, . | 12.4 | 101 |
| 40 | Tepotinib in Nonâ€"Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. New England Journal of Medicine, 2020, 383, 931-943. | 27.0 | 500 |
| 41 | Locally Advanced, Unresectable Non-Small Cell Lung Cancer. Current Oncology Reports, 2020, 22, 31. | 4.0 | 17 |
| 42 | Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer. Cancer Cell, 2020, 37, 639-654.e6. | 16.8 | 151 |
| 43 | Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. Journal of Thoracic Oncology, 2020, 15, 1449-1459. | 1.1 | 109 |
| 44 | Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients.. Journal of Clinical Oncology, 2020, 38, 9514-9514. | 1.6 | 68 |
| 45 | BRIGHTSTAR: A pilot trial of local consolidative therapy (LCT) with brigatinib in tyrosine kinase inhibitor (TKI)-naÃ¯ve ALK-rearranged advanced NSCLC.. Journal of Clinical Oncology, 2020, 38, 9624-9624. | 1.6 | 5 |
| 46 | Evolving Role of Immunotherapy in Recurrent Metastatic Head and Neck Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 899-906. | 4.9 | 24 |
| 47 | Tepotinib in patients (pts) with NSCLC with MET exon 14 (METex14) skipping: Health-related quality of life (HRQoL).. Journal of Clinical Oncology, 2020, 38, 9575-9575. | 1.6 | 1 |
| 48 | Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Cancer Cell, 2019, 36, 444-457.e7. | 16.8 | 145 |
| 49 | Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Nonâ€"small-cell Lung Cancer (NSCLC). Clinical Lung Cancer, 2019, 20, 43-47. | 2.6 | 45 |
| 50 | A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group. Journal of Thoracic Disease, 2018, 10, 3909-3921. | 1.4 | 35 |
| 51 | Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC. Clinical Cancer Research, 2018, 24, 6195-6203. | 7.0 | 292 |
| 52 | Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, 9052-9052. | 1.6 | 35 |
| 53 | Optimal regimen of cisplatin in squamous cell carcinoma of head and neck yet to be determined. Annals of Translational Medicine, 2018, 6, 229-229. | 1.7 | 26 |